Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control
posted on
Jan 28, 2023 09:47PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Companies can apply for early registration with 30% or greater ORR. As of the the AGM, 27 Oct 2022, there was 2 of 11 trials showing greater than 30% ORR. With 9 companies participating in those trials and one additional trial started since the AGM it wouldn't surprise me to see one of these companies try to tie up this technology before this years end. If my memory is correct, at the AGM DM said one of these 2 trials was at 30% ORR and the other at 40%.
tada